Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by blogon Oct 23, 2009 6:07pm
431 Views
Post# 16419230

RE: RE: RE: RE: RE: RE: Atrium

RE: RE: RE: RE: RE: RE: Atrium

WASKERWISK,

I believe you’re over confident and not informed enough to make the blanket statement “Macbeth is still right”. They may very well have the statistically significant data you have started talking about; after all it is single blind, with only 100 patients for the CE mark.

Two trials were recently completed this past August, also the have renal 2b in hand, wouldn't it be wonderful to have some deals/partnerships made soon.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities